Fig. 3

LRCC resistance is not due to increased proportion of the LRCC fraction or increased quiescence following exposure to gemcitabine. a Flow cytometry measuring Cy5-dUTP labelled cells (x-axis) are shown. Gemcitabine (at GI50 for individual cell line) was administered after 6 doubling times and measurements were taken after a total of 8 cycles. b Cell cycle distribution of LRCC and NLRCC cells without gemcitabine treatment, average of two cell lines of ≥2 independent experiments per cell line are shown. c Cell cycle distribution of gemcitabine treated LRCC and NLRCC cells, average of two cell lines of ≥2 independent experiments per cell line are shown. d Cell cycle distribution of gemcitabine treated and untreated LRCC cells, average of two cell lines of ≥2 independent experiments per cell line are shown